Evidence map›Paper›PMID 19566896›Full record

ArticleTraffic (Copenhagen, Denmark)2009

Involvement of vps33a in the fusion of uroplakin-degrading multivesicular bodies with lysosomes.

Xuemei Guo, Liyu Tu, Iwona Gumper, Heide Plesken, Edward K Novak, Sreenivasulu Chintala, Richard T Swank, Gregory Pastores, Paola Torres, Tetsuro Izumi and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Traffic (Copenhagen, Denmark), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. RAB27B requirement for stretch-induced exocytosis in bladder umbrella cells.American journal of physiology. Cell physiology · 2018
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Membrane traffic research: challenges for the next decade.Frontiers in cell and developmental biology · 2014
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Atg16L1 deficiency confers protection from uropathogenic Escherichia coli infection in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2012
    Article
  20. Targeting protein-trafficking pathways alters melanoma treatment sensitivity.Proceedings of the National Academy of Sciences of the United States of America · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Xuemei GuoDepartment of Cell Biology, New York University School of Medicine, New York, NY 10016, USA.
Liyu Tu
Iwona Gumper
Heide Plesken
Edward K Novak
Sreenivasulu Chintala
Richard T Swank
Gregory Pastores
Paola Torres
Tetsuro Izumi
Tung-Tien Sun
David D Sabatini
Gert Kreibich
New York University · USRoswell Park Comprehensive Cancer Center · USGunma University · JP

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Uroplakins and Baterial InfectionP01DK052206 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SUN, TUNG-TIEN · 1999 to 2015
$19.6M
BIOCHEMISTRY OF UROTHELIAL DIFFERENTIATIONR01DK039753 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SUN, TUNG-TIEN · 1987 to 2012
$4.6M
SYNTHESIS &DISTRIBUTION OF PROTEINS IN MEMBRANESR01GM043583 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SABATINI, DAVID D · 1991 to 2004
$2.3M
MOLECULAR ANALYSIS OF A HERMANSKY-PUDLAK SYNDROME GENER01EY012104 · NEI · ROSWELL PARK CANCER INSTITUTE CORP · PI SWANK, RICHARD T · 1998 to 2005
$1.8M
INHERITED DISEASES AFFECTING PLATELET FUNCTIONR01HL051480 · NHLBI · ROSWELL PARK CANCER INSTITUTE CORP · PI SWANK, RICHARD T · 1995 to 2004
$1.8M
MEGAKARYOCYTE-PLATELET GRANULES IN STORAGE POOL DISEASER01HL031698 · NHLBI · ROSWELL PARK CANCER INSTITUTE CORP · PI SWANK, RICHARD T · 1985 to 2004
$1.5M
NCI NIH HHS CA-16056NCI NIH HHS P30 CA016056NEI NIH HHS EY-12104NEI NIH HHS R01 EY012104NHLBI NIH HHS HL-31698NHLBI NIH HHS HL-51480NHLBI NIH HHS R01 HL031698NHLBI NIH HHS R01 HL051480NIDDK NIH HHS DK-39753NIDDK NIH HHS DK-52206NIDDK NIH HHS P01 DK052206NIDDK NIH HHS R01 DK039753NIGMS NIH HHS GM-43583NIGMS NIH HHS R01 GM043583PHS HHS 52206
6 · The paper itself

Abstract

The apical surface of the terminally differentiated mouse bladder urothelium is largely covered by urothelial plaques, consisting of hexagonally packed 16-nm uroplakin particles. These plaques are delivered to the cell surface by fusiform vesicles (FVs) that are the most abundant cytoplasmic organelles. We have analyzed the functional involvement of several proteins in the apical delivery and endocytic degradation of uroplakin proteins. Although FVs have an acidified lumen and Rab27b, which localizes to these organelles, is known to be involved in the targeting of lysosome-related organelles (LROs), FVs are CD63 negative and are therefore not typical LROs. Vps33a is a Sec1-related protein that plays a role in vesicular transport to the lysosomal compartment. A point mutation in mouse Vps33a (Buff mouse) causes albinism and bleeding (Hermansky-Pudlak syndrome) because of abnormalities in the trafficking of melanosomes and platelets. These Buff mice showed a novel phenotype observed in urothelial umbrella cells, where the uroplakin-delivering FVs were almost completely replaced by Rab27b-negative multivesicular bodies (MVBs) involved in uroplakin degradation. MVB accumulation leads to an increase in the amounts of uroplakins, Lysosomal-associated membrane protein (LAMP)-1/2, and the activities of beta-hexosaminidase and beta-glucocerebrosidase. These results suggest that FVs can be regarded as specialized secretory granules that deliver crystalline arrays of uroplakins to the cell surface, and that the Vps33a mutation interferes with the fusion of MVBs with mature lysosomes thus blocking uroplakin degradation.

Indexed as

AnimalsBlotting, WesternCells, CulturedLysosomal Membrane ProteinsLysosomesMembrane GlycoproteinsMembrane ProteinsMiceMice, Inbred C57BLMice, Mutant StrainsMicroscopy, ImmunoelectronMultivesicular BodiesPoint MutationProtein Transportrab GTP-Binding ProteinsUrinary BladderLysosomal Membrane ProteinsMembrane GlycoproteinsMembrane ProteinsRab27b protein, mouserab GTP-Binding ProteinsUpk2 protein, mouseUroplakin IIUroplakin IIIVesicular Transport ProteinsVps33a protein, mouse

Identifiers

PMID19566896
PMCPMC4494113
OpenAlexW2123014011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.